This is a working overview of Certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-27 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
=== Male competition === Because palpal, or genital bulb, movements from the males result in the displacement of spermatozoa and other seminal fluid from the female uterus externus, sperm competition exists between males of the P. Phalangioides species. A rival male can attempt to displace the sperm of another male from the female's genital cavity by copulating with her; however, because the copulation duration is greatly decreased in second males, and thus there is less time to displace a rival's sperm, it is unlikely that the spermatozoa of rival, second male would greatly outnumber those of the first male in the uterus externus.
The U.S. Institute of Medicine (renamed National Academy of Medicine in 2015) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for niacin in 1998, as well as Tolerable upper intake levels (ULs). In lieu of an RDA, Adequate Intakes (AIs) are identified for populations for which there is not enough evidence to identify a dietary intake level that is sufficient to meet the nutrient requirements of most people. (see table). The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values (DRV), with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. For the EU, AIs and ULs have the same definition as in the US, except that units are milligrams per megajoule (MJ) of energy consumed rather than mg/day. For women (including those pregnant or lactating), men and children the PRI is 1.6 mg per megajoule. As the conversion is 1 MJ = 239 kcal, an adult consuming 2390 kilocalories should be consuming 16 mg niacin. This is comparable to US RDAs (14 mg/day for adult women, 16 mg/day for adult men). ULs are established by identifying amounts of vitamins and minerals that cause adverse effects, and then selecting as an upper limit amounts that are the "maximum daily intake unlikely to cause adverse health effects". Regulatory agencies from different countries do not always agree. For the US, 30 or 35 mg of niacin for teenagers and adults, less for children.
Lifestyle modification (such as weight loss and exercise) and pain medications are the mainstays of treatment. Acetaminophen (also known as paracetamol) and NSAIDs (available as oral or topical formulations) are first line pain medications for symptomatic treatment of osteoarthritis. Medications that alter the course of the disease have not been found as of 2025. For overweight people, weight loss may help relieve pain due to hip arthritis. Recommendations include modification of risk factors through weight loss, increasing physical activity or exercise, healthy diet, management of contributing co-morbidities and adjustment of occupational factors that may contribute to osteoarthritis. Successful management of the condition is often made more difficult by differing priorities and poor communication between clinicians and people with osteoarthritis. Realistic treatment goals can be achieved by developing a shared understanding of the condition, actively listening to patient concerns, avoiding medical jargon, and tailoring treatment plans to the patient's needs. Recent research suggests that remote peer mentorship may help to improve self-management among people with hip or knee osteoarthritis who are experiencing socioeconomic disadvantage.
Sources: en.wikipedia.org
Measurements over 10 pCi/L warrant only another short-term test so that abatement measures are not unduly delayed. The EPA has advised purchasers of real estate to delay or decline a purchase if the seller has not successfully abated radon to 4 pCi/L or less. Because the half-life of radon is only 3.8 days, removing or isolating the source will greatly reduce the hazard within a few weeks. Another method of reducing radon levels is to modify the building's ventilation. Generally, the indoor radon concentrations increase as ventilation rates decrease. In a well-ventilated place, the radon concentration tends to align with outdoor values (typically 10 Bq/m3 (0.27 pCi/L), ranging from 1 to 100 Bq/m3 (0.027 to 2.703 pCi/L). The four principal ways of reducing the amount of radon accumulating in a house are:
Intracrine signaling is a mode of hormone and growth factor action in which signaling molecules exert their effects within the same cell that produces them, without being secreted into the extracellular environment. The term intracrine was originally coined to describe peptides that either act within the cell that synthesized them or function after being internalized by their target cells. While this model was initially developed through studies on the intracellular action of angiotensin II, it has since been recognized as a fundamental mechanism applicable to numerous peptide hormones and growth factors. Unlike classical endocrine, autocrine, and paracrine signaling, where signaling molecules leave the cell and interact with membrane-bound receptors, intracrine signaling functions exclusively within the intracellular environment, often targeting nuclear or cytoplasmic receptors. This mechanism allows cells to autonomously regulate essential biological functions, including gene expression, differentiation, and survival. One of the most well-characterized examples of intracrine signaling is the local synthesis and action of sex steroids within immune cells, which modulate inflammatory responses and metabolic pathways. The intracrine hypothesis has been instrumental in predicting novel functions for peptide hormones and has generated significant insights with potential therapeutic implications.
Sheikh Hazza bin Zayed bin Sultan Al Nahyan (Arabic: هزاع بن زايد بن سلطان آل نهيان; born 2 June 1965) is the younger brother of the President of the United Arab Emirates Sheikh Mohamed bin Zayed Al Nahyan, Ruler's Representative of Al Ain Region of the Emirate of Abu Dhabi, former National Security Advisor of the UAE and Deputy Chairman of Abu Dhabi Executive Council.
Integration of graphene (thickness of 0.34 nm) layers as nanoelectrodes into a nanopore can potentially solve a bottleneck for nanopore-based single-molecule DNA sequencing. On November 20, 2013, the Bill & Melinda Gates Foundation awarded $100,000 'to develop new elastic composite materials for condoms containing nanomaterials like graphene'. In 2014, graphene-based, transparent (across infrared to ultraviolet frequencies), flexible, implantable medical sensor microarrays were announced that allow the viewing of brain tissue hidden by implants. Optical transparency was greater than 90%. Applications demonstrated include optogenetic activation of focal cortical areas, in vivo imaging of cortical vasculature via fluorescence microscopy and 3D optical coherence tomography.
Sources: en.wikipedia.org
== Function == The activity of GSTs is dependent upon a steady supply of GSH from the synthetic enzymes gamma-glutamylcysteine synthetase and glutathione synthetase, as well as the action of specific transporters to remove conjugates of GSH from the cell. The primary role of GSTs is to detoxify xenobiotics by catalyzing the nucleophilic attack by GSH on electrophilic carbon, sulfur, or nitrogen atoms of said nonpolar xenobiotic substrates, thereby preventing their interaction with crucial cellular proteins and nucleic acids. Specifically, the function of GSTs in this role is twofold: to bind both the substrate at the enzyme's hydrophobic H-site and GSH at the adjacent, hydrophilic G-site, which together form the active site of the enzyme; and subsequently to activate the thiol group of GSH, enabling the nucleophilic attack upon the substrate. The glutathione molecule binds in a cleft between N- and C-terminal domains - the catalytically important residues are proposed to reside in the N-terminal domain. Both subunits of the GST dimer, whether hetero- or homodimeric in nature, contain a single nonsubstrate binding site, as well as a GSH-binding site. In heterodimeric GST complexes such as those formed by the cytosolic mu and alpha classes, however, the cleft between the two subunits is home to an additional high-affinity nonsubstrate xenobiotic binding site, which may account for the enzymes' ability to form heterodimers.
==== MeSH E05.196.867 – spectrum analysis ==== MeSH E05.196.867.151 – circular dichroism MeSH E05.196.867.519 – magnetic resonance spectroscopy MeSH E05.196.867.519.274 – electron spin resonance spectroscopy MeSH E05.196.867.519.550 – nuclear magnetic resonance, biomolecular MeSH E05.196.867.576 – optical rotatory dispersion MeSH E05.196.867.660 – pulse radiolysis MeSH E05.196.867.726 – spectrometry, fluorescence MeSH E05.196.867.776 – spectrometry, gamma MeSH E05.196.867.776.751 – spectroscopy, mossbauer MeSH E05.196.867.800 – spectrometry, x-ray emission MeSH E05.196.867.800.360 – electron probe microanalysis MeSH E05.196.867.826 – spectrophotometry MeSH E05.196.867.826.300 – microspectrophotometry MeSH E05.196.867.826.551 – spectrophotometry, atomic MeSH E05.196.867.826.676 – spectrophotometry, infrared MeSH E05.196.867.826.676.700 – spectroscopy, fourier transform infrared MeSH E05.196.867.826.802 – spectrophotometry, ultraviolet MeSH E05.196.867.838 – spectroscopy, electron energy-loss MeSH E05.196.867.838.500 – microscopy, energy-filtering transmission electron MeSH E05.196.867.851 – spectroscopy, near-infrared MeSH E05.196.867.877 – spectrum analysis, mass MeSH E05.196.867.877.500 – mass fragmentography MeSH E05.196.867.877.600 – spectrometry, mass, electrospray ionization MeSH E05.196.867.877.750 – spectrometry, mass, fast atom bombardment MeSH E05.196.867.877.755 – spectrometry, mass, matrix-assisted laser desorption-ionization MeSH E05.196.867.877.760 – spectrometry, mass, secondary ion MeSH E05.196.867.890 – spectrum analysis, raman
==== Two-compartment model ==== Not all body tissues have the same blood supply, so the distribution of the drug will be slower in those tissues than in others with a better blood supply. Furthermore, there are some tissues (such as the brain tissue) that present a real barrier to the distribution of drugs, which may be breached with greater or lesser ease depending on the drug's characteristics. If these relative conditions for the different tissue types are considered along with the rate of elimination, the organism can be considered to be acting like two compartments: one that we can call the central compartment, which has a more rapid distribution and consists of organs and systems with a well-developed blood supply; and the peripheral compartment, which is made up of organs with a lower blood flow. Other tissues, such as the brain, can occupy a variable position depending on a drug's ability to passively transport (high lipophilicity) and evade active efflux to cross the blood–brain barrier (BBB) that separates the organ from the blood supply. Two-compartment models vary depending on which compartment elimination occurs in. The most common situation is that elimination occurs in the central compartment as the liver and kidneys are organs with a good blood supply. However, in some situations, elimination occurs in the peripheral compartment or even in both compartments. This can mean that there are three possible variations in the two compartment model, which still do not cover all possibilities.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.